Literature DB >> 8387300

Lidocaine inhibits priming and protein tyrosine phosphorylation of human peripheral neutrophils.

T Kanbara1, M K Tomoda, E F Sato, W Ueda, M Manabe.   

Abstract

The addition of agents, such as tumor necrosis factor-alpha, to human peripheral neutrophils (HPPMN) induces priming, which enhances the receptor-mediated superoxide (O2-) generation and tyrosine phosphorylation of several HPPMN proteins. Lidocaine, a local anesthetic, inhibited both enhanced O2- generation and tyrosine phosphorylation of a 115 kDa protein in a concentration- and time-dependent manner. Lidocaine also inhibited protein kinase C sensitive O2- generation induced by phorbol myristate acetate, but not time dependently. Furthermore, lidocaine inhibited O2- generation by non-primed HPPMN induced by formylmethionyl-leucyl-phenylalanine, but this inhibition needed a higher concentration of lidocaine compared with that of primed HPPMN. These results suggest that lidocaine inhibits the priming step of neutrophil activation and that it is linked to the inhibition of tyrosine phosphorylation of a 115 kDa protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387300     DOI: 10.1016/0006-2952(93)90299-c

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth.

Authors:  Quan-Sheng Zhu; Ling Xia; Gordon B Mills; Clifford A Lowell; Ivo P Touw; Seth J Corey
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

2.  Protective effect of lidocaine in the experimental foot-and-mouth disease pancreatitis.

Authors:  E L Portiansky; P H González
Journal:  Experientia       Date:  1995-11-15

3.  Impact of epidural labor analgesia using sufentanil combined with low-concentration ropivacaine on maternal and neonatal outcomes: a retrospective cohort study.

Authors:  Le Zhang; Yue Li; Chengjie Xu
Journal:  BMC Anesthesiol       Date:  2021-09-22       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.